Genoway

Genoway Market capitalization

The The market capitalization of Genoway (ALGEN.PA) as of Nov 3, 2026 is 30.36 M EUR. In the previous year, The market capitalization was 30.36 M EUR — a change of 0.00% (lower).

Market capitalization

30.36 MEUR

YoY

0.00%

Last updated:

In 2025, Genoway's market cap stood at 30.36 M EUR, a 0.00% increase from the 30.36 M EUR market cap in the previous year.

The Genoway Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
30.36 M EUR
Jan 1, 2019
30.36 M EUR
Jan 1, 2020
30.36 M EUR
Jan 1, 2021
30.36 M EUR
Jan 1, 2022
30.36 M EUR
Jan 1, 2023
30.36 M EUR
Jan 1, 2024
30.36 M EUR
Jan 1, 2025
30.36 M EUR
The Genoway Market capitalization history
YEARMarket capitalizationYoY
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR0.00%
30.36 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Genoway's Market Capitalization

Genoway's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Genoway's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Genoway's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Genoway’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Genoway stock

The market capitalization of Genoway is 30.36 M EUR in 2025.

The market capitalization of Genoway changed from 30.36 M EUR to 30.36 M EUR, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Genoway since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's EUR, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' EUR varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Genoway with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genoway

All Key Metrics — Genoway